• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthChildcare
Europe

Nestlé is flying in emergency baby formula to the U.S. and running factories flat out to help ease critical shortage

Christiaan Hetzner
By
Christiaan Hetzner
Christiaan Hetzner
Senior Reporter
Down Arrow Button Icon
Christiaan Hetzner
By
Christiaan Hetzner
Christiaan Hetzner
Senior Reporter
Down Arrow Button Icon
May 17, 2022, 11:58 AM ET

Nestlé, Europe’s most valuable company, is ramping up production of hypoallergenic (HA) baby formula in an effort to serve the most pressing needs of infants amid an acute shortage in the United States.

In a statement sent to Fortune, the company said it “significantly increased” production of Gerber Good Start Extensive HA from the Netherlands and Alfamino from Switzerland, both used to treat babies that respond allergically to sugars like lactose.

“Both products were already being imported, but we moved shipments up and rushed via air to help fill immediate needs,” the Swiss food group said on Tuesday, confirming a report in Reuters.

“We prioritized these products because they serve a critical medical purpose as they are for babies with cow’s milk protein allergies.“

It is believed that as much as 5% of children aged three and below suffer from such an allergy and in rare cases of so-called immunoglobulin E (IgE) mediated allergies, it can be life threatening. Cow’s milk protein allergies are not to be confused with an intolerance for lactose, which is an inability to catalyze a specific dairy sugar. 

The same baby formula producer that had contaminated product and led to this shortage used billions of dollars to buy back stock instead of investing in their product safety. Putting profits before the safety of our children is unacceptable.

— Former Congresswoman Val Demings (@RepValDemings) May 13, 2022

Nestlé declined to be more specific on the size of increased shipments, some of which were being sent to hospitals directly, but the group said it was running formula factories flat out already.

Nevertheless it said it was just a “small player” in the U.S. infant formula market.

A recall by dominant provider Abbott Labs along with persistent supply-chain issues and a highly concentrated market combined to form what one consumer goods expert calls a “perfect storm”.

The shortage is affecting the supply of essential formula to millions of babies across the U.S. and it could last for months. 

The most recent statistics suggest Abbott, the manufacturer of Similac, had a 43% share of the market, while Mead Johnson, maker of Enfamil, controlled another 40%. By comparison, Nestlé was a distant third with just 15%. 

Since the mid-1990s, these three firms have been the sole infant formula manufacturers awarded government “WIC” contracts that target lower-income mothers often unable to breastfeed their children due to work. 

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
Christiaan Hetzner
By Christiaan HetznerSenior Reporter
Instagram iconLinkedIn iconTwitter icon

Christiaan Hetzner is a former writer for Fortune, where he covered Europe’s changing business landscape.

See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Most Popular

placeholder alt text
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House post
By Eleanor PringleFebruary 4, 2026
1 day ago
placeholder alt text
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving example
By Nick LichtenbergFebruary 4, 2026
1 day ago
placeholder alt text
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'
By Emma BurleighFebruary 3, 2026
2 days ago
placeholder alt text
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the board
By Jim EdwardsFebruary 4, 2026
1 day ago
placeholder alt text
Commentary
I've studied nonviolent resistance in war zones for 20 years and Minnesota reminds me of Colombia, the Philippines and Syria
By Oliver Kaplan and The ConversationFebruary 3, 2026
2 days ago
placeholder alt text
Investing
Ray Dalio warns the world is ‘on the brink’ of a capital war of weaponizing money—and gold is the best way for people to protect themselves
By Sasha RogelbergFebruary 4, 2026
1 day ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

Healthmattresses
Helix Mattress Review 2026: Tested by Sleep Experts
By Christina SnyderFebruary 5, 2026
2 hours ago
HealthDietary Supplements
The 6 Best Prebiotics of 2026: Tester Approved
By Christina SnyderFebruary 4, 2026
23 hours ago
Healthsleep
The Best Cooling Sheets of 2026: Personally Tested
By Christina SnyderFebruary 4, 2026
23 hours ago
A person sleeping in bed.
Healthsleep
What Is the Best Sleeping Position?
By Jessica RendallFebruary 4, 2026
1 day ago
C-Suitesubscription economy
The CEO of $11 billion Oura explains why customers must shell out for subscription fees after paying $349 or more for the ring
By Marco Quiroz-GutierrezFebruary 4, 2026
1 day ago
Healthsleep
7 Best Mattresses for Stomach Sleepers of 2026: Sleep Expert Tested
By Christina SnyderFebruary 4, 2026
1 day ago